Kanda dola\u015fan kanser h\u00fccrelerini tahlille tespit eden ak\u0131ll\u0131 \u00e7ip teknolojisinden sevindiren haber… ODT\u00dc Teknokent ara\u015ft\u0131rmac\u0131lar\u0131n\u0131n geli\u015ftirdi\u011fi sistem 300 hasta \u00fczerinde denenmeye ba\u015flad\u0131.<\/b><\/p>\n
ODT\u00dc Teknokent ara\u015ft\u0131rmac\u0131lar\u0131n\u0131n yedi y\u0131l \u00fczerinde \u00e7al\u0131\u015ft\u0131klar\u0131, kanda dola\u015fan kanser h\u00fccrelerini basit bir kan tahliliyle yakalayan \u201cak\u0131ll\u0131 \u00e7ip\u201d teknolojisinde sona yakla\u015f\u0131ld\u0131.<\/p>\n
Hasta i\u00e7in ac\u0131 verici ve maliyetli bir y\u00f6ntem olan i\u011fne biyopsisinin yerine kullan\u0131lmas\u0131 hedeflenen yeni y\u00f6ntem i\u00e7in Ankara\u2019daki d\u00f6rt hastanede klinik ara\u015ft\u0131rmalar ba\u015flat\u0131lacak.<\/p>\n
ODT\u00dc Elektrik Elektronik M\u00fchendisli\u011fi B\u00f6l\u00fcm\u00fc \u00d6\u011fretim \u00dcyesi ve Mikro Biyosistemler Genel M\u00fcd\u00fcr\u00fc Prof. Dr. Haluk K\u00fclah, Mikro Biyosistemler\u2019in, ODT\u00dc Teknokent\u2019te 2015\u2019te kuruldu\u011funu belirtti.<\/p>\n
K\u00fclah, \u0130ngiltere\u2019de \u00f6nemli biyoteknoloji firmalar\u0131na ev sahipli\u011fi yapan bir teknopark olan Alderley Park\u2019ta ge\u00e7en y\u0131l kurduklar\u0131 \u201cCellsway\u201d isimli \u015firket arac\u0131l\u0131\u011f\u0131yla uluslararas\u0131 klinik ara\u015ft\u0131rma faaliyetlerini s\u00fcrd\u00fcrd\u00fcklerini anlatt\u0131.<\/p>\n
L\u0130K\u0130T B\u0130YOPS\u0130 TEKN\u0130\u011e\u0130<\/strong><\/p>\n T\u00fcm\u00f6r kitlesinden ayr\u0131larak kana ge\u00e7en kanser h\u00fccrelerinin, \u201cdola\u015f\u0131mdaki t\u00fcm\u00f6r h\u00fccreleri (CTC)\u201d olarak adland\u0131r\u0131ld\u0131\u011f\u0131n\u0131 ifade eden Prof. Dr. K\u00fclah, bu h\u00fccrelerin kandan ayr\u0131\u015ft\u0131r\u0131labilmesi i\u00e7in \u00e7ok y\u00fcksek hassasiyette bir sistem gerekti\u011fini, geli\u015ftirdikleri yeni teknolojinin bu alanda pek \u00e7ok ilki bar\u0131nd\u0131rd\u0131\u011f\u0131n\u0131 s\u00f6yledi.<\/p>\n Kanser hastal\u0131\u011f\u0131n\u0131n tan\u0131 ve takibinde rutin kullan\u0131lan, i\u011fne biyopsisinde cerrahi bir i\u015flemle hastan\u0131n kanserli dokusundan \u00f6rnek al\u0131nan y\u00f6ntemin hasta i\u00e7in ac\u0131 verici ve maliyetli bir y\u00f6ntem oldu\u011funa i\u015faret eden K\u00fclah, Mikro-Elektromekanik Sistemler (MEMS) ve mikro ak\u0131\u015fkan teknolojilerinin kullan\u0131ld\u0131\u011f\u0131 likit biyopsi tekni\u011fiyle kan \u00f6rne\u011finde kanser h\u00fccrelerini yakalad\u0131klar\u0131n\u0131 anlatt\u0131.<\/p>\n \u201cTASARIM VE PATENT TAMAMEN B\u0130ZE A\u0130T\u201d<\/strong><\/p>\n Kan tahlili ile kanserin metastaz ve tekrarlama riskleri ve tedavi s\u00fcrecine ili\u015fkin bilgilere ula\u015fabildiklerini belirten Haluk K\u00fclah, \u015fu bilgileri verdi:<\/p>\n \u201cKan tahlilinde kanser h\u00fccrelerini yakalamak \u00fczere MEMS teknolojisi ile geli\u015ftirdi\u011fimiz silisyum tabanl\u0131 \u00e7iplerin tasar\u0131m\u0131 ve patenti tamamen bize ait. Bu \u00e7iplere ak\u0131ll\u0131 \u00e7ipler diyoruz. Ak\u0131ll\u0131 \u00e7iplerin i\u00e7inde k\u0131lcal damarlar gibi ufak mikro kanallar var. Bu kanallardan kan h\u00fccrelerini tek tek ge\u00e7iriyoruz ve bu s\u0131rada \u00e7ipin i\u00e7indeki mekanik yap\u0131lar ayr\u0131\u015ft\u0131rma yaparak kanser h\u00fccrelerini bir tarafta, kanser olmayan h\u00fccreleri de ba\u015fka tarafta topluyor. As\u0131l kanser h\u00fccrelerini i\u00e7eren \u00f6rnekte de birtak\u0131m analizler yaparak kanserin t\u00fcr\u00fcne ve hangi tip kemoterapinin i\u015fe yarayaca\u011f\u0131na dair bilgileri topluyoruz.\u201d<\/p>\n 300 HASTA \u00dcZER\u0130NDE DENEN\u0130YOR<\/strong><\/p>\n Prof. Dr. Haluk K\u00fclah, geli\u015ftirdikleri sistemdeki do\u011fruluk oranlar\u0131n\u0131n y\u00fcksek oldu\u011funu ve rakiplerine kar\u015f\u0131 daha \u00fcst\u00fcn bir performans sergiledi\u011fini belirtti.<\/p>\n K\u00fclah, yedi y\u0131ld\u0131r \u00fczerinde \u00e7al\u0131\u015ft\u0131klar\u0131 teknolojide geldikleri a\u015famaya ili\u015fkin, \u201cCihaz\u0131m\u0131z ve ara\u015ft\u0131rma faaliyetlerimiz tamamland\u0131. Laboratuvarlarda klinik \u00e7al\u0131\u015fma yapabilecek a\u015famaya geldik. Yak\u0131n zamanda 300 hasta \u00fczerinde klinik \u00e7al\u0131\u015fma ba\u015flatt\u0131k. B\u00f6ylece ara\u015ft\u0131rma ama\u00e7l\u0131 olarak ger\u00e7ek hastalar \u00fczerinde kan testi ile kanser tan\u0131s\u0131 ve tedavisinin takibini yapabilece\u011fiz.\u201d dedi.<\/p>\n SA\u011eLIK S\u0130GORTASIYLA YAPTIRILAB\u0130LECEK<\/strong><\/p>\n Projenin Bilimsel Direkt\u00f6r\u00fc Biyokimya Uzman\u0131 Do\u00e7. Dr. Ebru \u00d6zg\u00fcr, 2015\u2019ten beri \u00fczerinde \u00e7al\u0131\u015ft\u0131klar\u0131 sistemin, \u00f6n klinik \u00e7al\u0131\u015fmalar\u0131 da i\u00e7eren validasyon s\u00fcre\u00e7lerinin tamamlanarak laboratuvarlarda test edilebilir a\u015famaya geldi\u011fini bildirdi.<\/p>\n Klinik a\u015famada hasta \u00f6rnekleri ile \u00e7al\u0131\u015fmalara ba\u015flayacaklar\u0131n\u0131 belirten \u00d6zg\u00fcr, \u201cSistemimizi yak\u0131n zamanda laboratuvarlara ve hastanelere kuraca\u011f\u0131z.\u201d dedi.<\/p>\n Geli\u015ftirdikleri \u201clikit biyopsi\u201d ad\u0131 verilen y\u00f6ntemlerinde direkt kan \u00f6rne\u011finden t\u00fcm\u00f6rle ilgili bilgileri alabildiklerini belirten \u00d6zg\u00fcr, \u201cKanser h\u00fccrelerinin analizi ile kemoterapi, radyoterapi ya da hedefli ila\u00e7 tedavisi ba\u015flanan hastada bu tedavinin i\u015fe yaray\u0131p yaramad\u0131\u011f\u0131n\u0131 ve hangi tedavinin uygun olabilece\u011fine ili\u015fkin doktora bilgi veriyoruz. Onkologlar verdi\u011fimiz bu sonu\u00e7lar ile hastaya y\u00f6nlendirme yapabiliyorlar.\u201d diye konu\u015ftu.<\/p>\n BAZI MERKEZLERE S\u0130STEM KURULDU<\/strong><\/p>\n Geli\u015ftirdikleri sistemin, \u201cara\u015ft\u0131rma\u201d ama\u00e7l\u0131 olarak kullan\u0131ld\u0131\u011f\u0131n\u0131, Ankara ve \u0130stanbul\u2019daki baz\u0131 merkezlere sistemi kurduklar\u0131n\u0131 aktaran Ebru \u00d6zg\u00fcr, \u015fu bilgileri verdi:<\/p>\n \u201c\u00c7al\u0131\u015fmam\u0131za, meme kanseri, kolon kanseri ve k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri hastalar\u0131 dahil olacak. Ayn\u0131 zamanda sa\u011fl\u0131kl\u0131 bireylerden de \u00f6rnekler alaca\u011f\u0131z. Bunlar\u0131n sonu\u00e7lar\u0131n\u0131 kar\u015f\u0131la\u015ft\u0131rmal\u0131 bir \u015fekilde sunaca\u011f\u0131z. \u00c7al\u0131\u015fmam\u0131z, bir y\u0131l i\u00e7inde tamamlanacak ve o zaman s\u00fcrecin validasyonu tamamlanm\u0131\u015f olacak. Geli\u015ftirdi\u011fimiz cihaz, in vitro dedi\u011fimiz v\u00fccut d\u0131\u015f\u0131 tan\u0131 cihaz\u0131 kategorisine girdi\u011finden CE ve FDA onay\u0131 almak i\u00e7in ba\u015fvurular\u0131m\u0131z\u0131 yapaca\u011f\u0131z. Onaylar\u0131m\u0131z\u0131 ald\u0131\u011f\u0131m\u0131zda hastalar mevcut sa\u011fl\u0131k sigortalar\u0131 ile bu testleri yapt\u0131rabilecekler. Bu y\u0131l\u0131n sonu itibar\u0131yla ise doktorlar\u0131n onay\u0131 olmas\u0131 kayd\u0131yla belli ba\u015fl\u0131 hastanelerde tedavi g\u00f6ren kanser hastalar\u0131, klinik \u00e7al\u0131\u015fmam\u0131z kapsam\u0131nda kan tahlili ile takip kapsam\u0131na al\u0131nacak.\u201d (AA)<\/p>\n","protected":false},"excerpt":{"rendered":" Kanda dola\u015fan kanser h\u00fccrelerini tahlille tespit eden ak\u0131ll\u0131 \u00e7ip teknolojisinden sevindiren haber… ODT\u00dc Teknokent ara\u015ft\u0131rmac\u0131lar\u0131n\u0131n …<\/p>\n","protected":false},"author":1,"featured_media":43358,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[159,169,1934,685,586],"class_list":["post-43357","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-hasta","tag-kan","tag-kanser","tag-sistem","tag-tek"],"_links":{"self":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/43357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43357"}],"version-history":[{"count":1,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/43357\/revisions"}],"predecessor-version":[{"id":43359,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/43357\/revisions\/43359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/media\/43358"}],"wp:attachment":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}